MEDIPOST has been selected as a new conducting company of ‘global high-tech biomedicine development project’ run by Ministry of Science, ICT and Future Planning and Ministry of Health and Welfare.

This project has been propelled in order to develop top global bio companies and global high-tech biomedicine, and 4 companies have been selected in stem cell treatment and genetic treatment areas to be invested 40,000,000,000 won for 3 years.

MEDIPOST is the only company selected in the stem cell treatment area, enhancing statue of local representative stem cell company.

MEDIPOST has been selected as a conducting company for the project with a task ‘Pipeline development for each disease and platform development for next generation stem cell treatment to leap globally (Chief investigator: Won-Il Oh)’.

The main tasks of the project include performing clinical trials of ‘CARTISTEM^®‘ in Japan and acquiring approval, and developing a platform for SMUP-Cell and also developing new pipelines.